Uptick Newswire Hosts Khiron Life Sciences Corp.’s President to Discuss the Growing Latin American Cannabis Market and How They Have Positioned Themselves as a Leader
PHOENIX, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast features Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: 4KH), an integrated medical cannabis company with its core operations in Colombia. President of the company, Chris Naprawa, talked with Stock Day’s Everett Jolly.
“Khiron is positioned to be the dominant integrated medical cannabis company in Latin America,” Naprawa said as he started the interview. “This is a market of 620 million people, so that’s bigger than Canada, the United States, and Germany combined.”
Naprawa went on to say they’ve been at this for two years and have assembled an elite group of people and have a $75 million market share cap. Jolly then asked how the Latin American legal cannabis market compares to the US and Canada.
“You need to have a great deal of expertise to understand these markets because it’s not a singular market, of course,” explained Naprawa. “I think the biggest news to hit the world is that Mexico is going full legal adult use and medicinal, that’s going to happen in the first half of 2019.”
He describes the news as a real “game changer” in the cannabis business. The company is based out of Columbia, which is a medical market. He went on to describe how the landscape is changing in various Latin American companies.
“Rather than being the 125th LP to compete in Canada, we want to be the number one company in these markets,” said Naprawa.
Jolly then mentioned all of the licenses that come along in the cannabis business and asked how Khiron is positioned in the Latin American markets. Naprawa said many of their peers are focused on low cost cultivation for export into foreign markets, but they have a different approach.
“We are very focused on selling branded products into that market. Take the low cost cultivation but have big margins, sales, brand, and execution in region we are trying to operate,” he explained.
Jolly then asked about the recent acquisition of the Latin American Institute of Neurology and the Nervous System (“ILANS”). Naprawa says it’s about getting close to the medical marijuana patients.
“Doctors won’t prescribe medication that their medical association won’t endorse. We’ve been very much focused on educating those associations, getting those endorsements.”
He then went on to explain that the next part was dealing with patients and clinics. That’s where the partnership with ILANS comes in. ILANS is one of the most respected, fastest growing, and largest health service network providers in Colombia and Latin America. The ILANS network represents 100,000 patients in Colombia.
“These folks are exactly the types of patients we are looking for, they fit the profile perfectly. As we worked on partnerships with ILANS it became clear if we could strike a deal, we could own that. We were able to close that deal last week,” he said.
Naprawa says a deal like this helps expedite the patient process and lets them conduct their own clinical trials.
To hear the entire interview, listen to the Stock Day podcast: https://upticknewswire.com/featured-interview-president-chris-naprawa-of-khiron-life-sciences-corp-otcqb-khrnf/
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: 4KH) (“Khiron” or the “Company”) is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.
With a focused regional strategy and patient-oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes the former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
T: +1 (416) 705-1144
Chief Financial Officer
T: +1 (705) 527-3564
Vice President, Communications
T: +1 (416) 543-9179
This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
Released December 20, 2018